Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of DO-2 in advanced or refractory solid tumors
NL-OMON59589Phase 1Recruiting
- Sponsor
- DeuterOncology
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of do-2 in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) (2 arms), sponsored by DeuterOncology. Started Jul 2023; status: recruiting.
02
Drugs
do-2
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59589.